{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CROHN%27S+DISEASE&page=29", "query": { "condition": "CROHN'S DISEASE", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 685, "total_pages": 69, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CROHN%27S+DISEASE&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CROHN%27S+DISEASE&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T16:39:21.704Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03105102", "title": "A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Placebo for Risankizumab SC", "type": "DRUG" }, { "name": "Risankizumab IV", "type": "DRUG" }, { "name": "Placebo for Risankizumab IV", "type": "DRUG" }, { "name": "Risankizumab SC", "type": "DRUG" }, { "name": "Risankizumab On-Body Injector (OBI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 1336, "start_date": "2018-04-09", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 111, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03105102" }, { "nct_id": "NCT03759288", "title": "An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Crohn's Disease", "IBD" ], "interventions": [ { "name": "Brazikumab low dose", "type": "DRUG" }, { "name": "Brazikumab high dose", "type": "DRUG" }, { "name": "Humira®", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 89, "start_date": "2018-12-07", "completion_date": "2023-10-18", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lancaster", "state": "California" }, { "city": "Lincoln", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03759288" }, { "nct_id": "NCT01696942", "title": "Cimzia Versus Mesalamine for Crohn's Recurrence", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Cimzia", "type": "DRUG" }, { "name": "Mesalamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-02", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2018-01-12", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01696942" }, { "nct_id": "NCT01224171", "title": "Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "vedolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 416, "start_date": "2010-11", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2014-07-21", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 40, "location_summary": "Lafayette, Colorado • Hamden, Connecticut • Gainesville, Florida + 36 more", "locations": [ { "city": "Lafayette", "state": "Colorado" }, { "city": "Hamden", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01224171" }, { "nct_id": "NCT03798405", "title": "Reactive vs. Proactive Pain Control in IBD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Inflammatory Bowel Diseases", "Pain", "Opioid Use", "Crohn Disease", "Ulcerative Colitis" ], "interventions": [ { "name": "Proactive Analgesic Inpatient Narcotic-Sparing", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-01-01", "completion_date": "2022-07-01", "has_results": false, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03798405" }, { "nct_id": "NCT03816345", "title": "Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autoimmune Disease", "Crohn Disease", "Dermatomyositis", "Hematopoietic and Lymphoid Cell Neoplasm", "Inflammatory Bowel Disease", "Malignant Solid Neoplasm", "Multiple Sclerosis", "Psoriasis", "Psoriatic Arthritis", "Rheumatoid Arthritis", "Sjogren Syndrome", "Systemic Lupus Erythematosus", "Systemic Scleroderma", "Ulcerative Colitis" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Fluoropyrimidine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Platinum Compound", "type": "DRUG" }, { "name": "Platinum Doublet", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2019-07-16", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816345" }, { "nct_id": "NCT02531113", "title": "Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "RPC1063", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 69, "start_date": "2015-10-09", "completion_date": "2019-11-28", "has_results": true, "last_update_posted_date": "2021-01-22", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 13, "location_summary": "Tucson, Arizona • Largo, Florida • Palmetto Bay, Florida + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Largo", "state": "Florida" }, { "city": "Palmetto Bay", "state": "Florida" }, { "city": "Suwanee", "state": "Georgia" }, { "city": "Oak Lawn", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02531113" }, { "nct_id": "NCT03747718", "title": "Randomized Trial Comparing Single vs. Maintenance Fecal Microbiota Transplant for Refractory Crohn's Disease in Children", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "Fecal Microbiota Transplantation", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 0, "start_date": "2022-12-01", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03747718" }, { "nct_id": "NCT00482092", "title": "Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Prochymal®", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mesoblast, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 330, "start_date": "2007-09-17", "completion_date": "2014-09-15", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 47, "location_summary": "Los Angeles, California • San Francisco, California • Wheat Ridge, Colorado + 38 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00482092" }, { "nct_id": "NCT00790933", "title": "An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis", "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2243, "start_date": "2009-05-22", "completion_date": "2017-10-31", "has_results": true, "last_update_posted_date": "2022-05-24", "last_synced_at": "2026-10-14T16:39:21.704Z", "location_count": 31, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Lafayette", "state": "Colorado" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00790933" } ] }